NAV

Ebastine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Ebastine is a second generation H1-receptor antagonist useful in the treatment of allergic rhinitis and urticaria.

Generic Name
Ebastine
DrugBank Accession Number
DB11742
Background

Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.

Type
Small Molecule
Groups
Approved, Investigational
Structure
3D
Similar Structures
Weight
Average: 469.6576
Monoisotopic: 469.298079497
Chemical Formula
C32H39NO2
Synonyms
  • Ebastina
  • Ebastine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofAllergic rhinitis (ar)••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hover over products below to view reaction partners

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Ebastine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbametapirThe serum concentration of Ebastine can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Ebastine can be increased when combined with Abatacept.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Ebastine.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Ebastine.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ebastine.
Food Interactions
  • Take with or without food. Taking ebastine with food may increase its bioavailability.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
R06AX22 — Ebastine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Alkyl-phenylketones / Phenylbutylamines / Butyrophenones / Phenylpropanes / Benzylethers / Benzoyl derivatives / Aryl alkyl ketones / Piperidines / Gamma-amino ketones / Trialkylamines
show 5 more
Substituents
Alkyl-phenylketone / Amine / Aromatic heteromonocyclic compound / Aryl alkyl ketone / Aryl ketone / Azacycle / Benzoyl / Benzylether / Butyrophenone / Dialkyl ether
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
TQD7Q784P1
CAS number
90729-43-4
InChI Key
MJJALKDDGIKVBE-UHFFFAOYSA-N
InChI
InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
IUPAC Name
1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one
SMILES
CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
  1. Apotheke.de: Ebastine Aristo orodispersible tablets [Link]
Human Metabolome Database
HMDB0060159
PubChem Compound
3191
PubChem Substance
347828100
ChemSpider
3079
BindingDB
22873
RxNav
23796
ChEBI
31528
ChEMBL
CHEMBL305660
ZINC
ZINC000003781952
Wikipedia
Ebastine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedTreatmentIrritable Bowel Syndrome (IBS)2
4CompletedTreatmentUrticaria1
3RecruitingTreatmentIrritable Bowel Syndrome (IBS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SyrupOral1 MG/ML
TabletOral10 mg
Tablet, film coatedOral10 MG
Tablet, film coatedOral20 MG
Tablet, orally disintegratingOral10 MG
Tablet, orally disintegratingOral20 MG
TabletOral20.000 mg
WaferOral10 mg
Film, solubleOral10 MG
Film, solubleOral20 MG
SyrupOral5 MG/5ML
Tablet, film coatedOral10.00 mg
Film, solubleOral
SyrupOral
Tablet, film coatedOral
Tablet, coatedOral10 mg
SolutionOral0.1 g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.47e-05 mg/mLALOGPS
logP6.89ALOGPS
logP6.96Chemaxon
logS-6.9ALOGPS
pKa (Strongest Acidic)16.45Chemaxon
pKa (Strongest Basic)8.43Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area29.54 Å2Chemaxon
Rotatable Bond Count10Chemaxon
Refractivity145.38 m3·mol-1Chemaxon
Polarizability55.41 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-014i-1941000000-bcc59998a2c37520b0d8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gi0-0930400000-a3b7001dd8bec489cf92
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dr-0260900000-b16d2f94c7e55b626592
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0000900000-bb76f3ce793d6740b1e2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ukc-5471900000-c112b73337a748e5cf32
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0942800000-7a43204fde96be00b1e0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-006x-4912200000-a0e0373f427660170825
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0991-0940100000-4b209888b8f318a7ec13
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-231.2158895
predicted
DarkChem Lite v0.1.0
[M-H]-230.5903895
predicted
DarkChem Lite v0.1.0
[M-H]-207.67299
predicted
DeepCCS 1.0 (2019)
[M+H]+232.5761895
predicted
DarkChem Lite v0.1.0
[M+H]+231.8845895
predicted
DarkChem Lite v0.1.0
[M+H]+210.031
predicted
DeepCCS 1.0 (2019)
[M+Na]+231.9172895
predicted
DarkChem Lite v0.1.0
[M+Na]+232.9426895
predicted
DarkChem Lite v0.1.0
[M+Na]+216.12416
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Imamura Y, Shimizu K, Yamashita F, Yamaoka K, Takakura Y, Hashida M: Transport characteristics of ebastine and its metabolites across human intestinal epithelial Caco-2 cell monolayers. Biol Pharm Bull. 2001 Aug;24(8):930-4. doi: 10.1248/bpb.24.930. [Article]
  2. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Details2. Cytochrome P450 3A Subfamily (Protein Group)
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Components:
NameUniProt ID
Cytochrome P450 3A4P08684
Cytochrome P450 3A43Q9HB55
Cytochrome P450 3A5P20815
Cytochrome P450 3A7P24462
References
  1. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]

Drug created at October 20, 2016 20:43 / Updated at May 27, 2021 02:57